May 2nd 2024
The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.
What to Know about the Aprocitentan Approval for Resistant Hypertension, with Michael Weber, MD
March 25th 2024Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.
Alirocumab Approved for Heterozygous Familial Hypercholesterolemia in Patients 8 Years and Older
March 11th 2024Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.